AU716883B2 - Antibiotics - Google Patents

Description

WO 96/35701 PCTIGB96/01144

ANTIBIOTICS

The invention relates to N-alkyl-N-glycosyl derivatives of alkyl esters of antifungal antibiotics of the polycne macrolide group of general formula wherein M represents polyene macrolide antibiotics residues, R represents a variable part of sugar residue, and each of RI and R 2 which may be the same or different, represents a Cl.4 alkyl group; to salts of compound represented by the general formula wherein M, R, R 1 and R 2 are as defined above and A represents an anion of an inorganic or organic acid; to methods of preparation of compounds of general formula 1(a) and 2(a) and their use in medicine.

Compounds of particular interest include N-methyl-N-glycosyl derivatives of methyl esters of antifungal antibiotics of polyene macrolide group of general formula wherein M represents polyene macrolide antibiotics residues, wherein R represents a variable part of sugar residue, and their salts of general formula wherein M represents polyene macrolide antibiotics residues, wherein R represents a variable part of sugar residue, and A represents an anion of inorganic or organic acid, and to methods of their preparation, and .0 .6 use in medicine.

*e .15 N-alkyl derivatives of antibiotics of polyene macrolide group wherein the amino group of the parent antibiotic is substituted by an alkyl group are known.

N-glycosyl derivatives of polyene macrolides wherein amino group of the parent antibiotic is substituted with a residue of sugar are also known Antibiotics 2S, 244 (1975), L. Falkowski, J. Golik, P. Kolodziejczvk, J. Pawlak, J. Zielinski, T. Zimiiski, E.

0* 20 Borowski; Acta Polon. Pharm. 37. 517 (1980), L. Falkowski, J. Pawlak, J. Golik, P.

Kolodziejczyk, B. Stefaiska, E. Bylec, E. Borowski). Examples of sugars used in the preparation of these derivatives include D-glucose, D-mannose, L-rhamnose, D-ribose and ~maltose. Upon reaction of polyene macrolides with the appropriate sugar a simultaneous Amadori rearrangement occurs to give the corresponding N-glycosyl derivatives. The 25 compounds have the advantage that they exhibit a biological activity similar to those of the starting antibiotics and form water soluble salts. However, the high toxicity associated therewith represents a significant disadvantage.

From papers J. Antibiotics 2, 244 (1975), L. Falkowski, J. Golik, P. Kolodziejczyk, J. Pawlak, J. Zieliiski, T. Zimiiski, E. Borowski; Acta Polon. Pharm. 12, 517 (1980), L. Falkowski, J. Pawlak, J. Golik, P. Kolodziejczvk, B. Stefafiska, E. Bylec. E. Borowski), -1- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 there are known N-glycosyl derivatives of polyene macrolides, in which the amino group of the parent antibiotic is substituted with a residue of sugar, such as D-glucose, D-mannose, L-rhamnose, D-ribose, maltose. The compounds are prepared by reaction of polyene macrolides with the listed sugars, and simultaneous Amadori rearrangement. The compounds exhibit the biological activity similar to those of the starting antibiotics and form water soluble salts. However, they exhibit high toxicity.

Trimethylammonium derivatives of polyene macrolides methyl esters wherein the amino group of the parent antibiotic is fully methylated to give a quaternary ammonium salt are also known Antibiotics 22, 1080 (1979), L. Falkowski, B. Stefariska, J. Zielifiski, E.

Bylec, J. Golik, P. Kolodziejczyk, E. Borowski). The compounds are prepared by exhaustive methylation of the parent antibiotic with dimethyl sulphate. Advantageous properties of the derivatives include their solubility in water and an antifungal activity similar to that of the starting antibiotics. Unfortunately they are very toxic and unstable.

Another type of derivatives are trimethylammonium derivatives of polyene macrolides methyl esters, which are known from a paper J. Antibiotics 32, 1080 (1979), L. Falkowski, B. Stefaiska, J. Zieliiski, E. Bylec, J. Golik, P. Kolodziejczyk, E. Borowski and in these compounds the amino group of the antibiotic methyl esters is fully methylated to give quatemary ammonium salt. The compounds are prepared by exhaustive methylation of the parent antibiotic with dimethyl sulphate. The derivatives are soluble in 00 20 water and are characterized by antifungal activity similar to the activity of the starting antibiotics, but they are very toxic and unstable.

Other types of N-alkyl derivatives include the N-succinimidyl derivatives formed by Michael addition reaction of the antibiotics and N-substituted maleimides, such as: N-ethylmaleimide, N,N'-hexamethylenedimaleimide, N-(3-dimethylaminopropyl)t 25 maleimide; the compounds are known from a paper J. Antibiotics, 44, 979 (1991), S* A. Czerwiiski, W.A. K6nig, T. Zieniawa, P. Sowisfiki, V. Sinnwell, S. Milewski.

E. Borowski. Such compounds are less toxic than the parent antibiotics, but their antifungal activity is diminished.

Finally, the last known group of N-alkyl derivatives of polyene macrolides are N-enamine and amidine derivatives, formed by reaction of the antibiotics with acetylacetone, ethyl acetylacetate, dimethylacetal or dimethylformamide; the compounds Mimosa 10/14/1997 13:57:49 WO 96/35701 PCTIGB96/ 1144 are presented in a paper Acta Polonica Phann. 45, 71 (1988), B. Stefaiska, J. Zieliiski, E. Borowski, L. Falkowski. The derivatives exhibit antifungal activity similar to those of the parent antibiotics and improved solubility in organic solvents, however, they are still significantly toxic and very unstable.

The present inventors have now prepared mixed N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics. Methods of preparation of these mixed compounds have also been established. These novel compounds have been found to have high anti-fungal activity, similar to those of the parent antibiotics; form water soluble salts with acids; and are significantly less toxic. These properties are unexpected since all of the N-alkyl derivatives of polyene macrolides of the prior art exhibit a high toxicity, which is a considerable disadvantage. The compounds comprised by the invention are devoid of this disadvantage.

Until now, N-methyl-N-glycosyl derivatives of methyl esters of polyene macrolide antibiotics and methods of their preparation were unknown. Surprisingly, such compounds 9 15 preserve high antifungal activity, similar to those of the parent antibiotics, they form water S. soluble salts with acids, and are dramatically less toxic. These compounds do not exhibit the same toxicity as the N-alkyl derivatives of the prior art. A high toxicity constitutes the abasic drawback of all known before N-alkyl derivatives of polyene macrolides, and the compounds comprised by the invention are devoid of this disadvantage.

20 A first aspect of the invention provides N-alkyl-N-glycosvl derivatives of alkyl esters a.* of antibiotics of polyene macrolide group of general formula wherein M represents residue of an antibiotic of polyene macrolide group, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharidc, and each of R 1 and

R

2 which may be the same or different, represents CI 4 alkyl group.

M COOR 2 R R'-N-CH HO R Formula l(a) Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 Preferably the residue of the antibiotic ofpolyene macrolide group M is selected from amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin or candicidin.

It is preferred that the mono or oligosaccharide from which the sugar residue R is derived is selected from D-glucose, or L-glucose, or D-mannosc, or D-galactose, or lactose, or maltose. Upon reaction of polyene macrolides with the appropriate sugar a simultaneous Amadori rearrangement occurs to give the N-glycosyl precursors to the compounds of the invention.

A preferred embodiment of the invention comprises N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement.

M-COOCH

3 i

H

3 C-N-CH2 HO R 9..

9 15 Formula 1(b) y* The invention in its preferred form relates to the derivatives wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or 4*99 mycoheptin, or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or S I candicidin.

20 A second aspect of the invention provides salts of N-alkyl-N-glycosyl derivatives of antibiotics of polyene macrolide group of general formula 2(a) wherein M, R, R 1 and R 2 are as defined above for the first aspect of the invention and A represents an anion of an organic or inorganic acid. It is preferred that the salt is a physiologically acceptable salt and compounds wherein A is the anion of L-aspartic acid are especially preferred. Salts wherein

R

1 and R- are methyl groups are especially preferred.

-4- Mimosa 10/14/1997 13:57:49 I I WO 96/35701 PCTIGB96/01144

M-COOR

2

I

R

1

-N-CH

2 A0 I /A H C HO R Formula 2(a) A preferred embodiment of the second aspect of the invention comprises salts of Nmethyl-N-glycosyl derivatives of antibiotics of polyene macrolide group presented by general formula 2(b) wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or Dgalactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid.

M -COOCH3

H

3

C-N-CH

2 EA A I

A

C

HO R -Formula 2(b) 10 The invention in its preferred form relates to the salts wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or mycoheptin. or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or candicidin, and also preferably A relates to the anion of L-aspartic acid.

A third aspect of the invention comprises a method of preparation of compounds of formula 1(a) wherein M, R, R 1 and R 2 are as defined above for the first and second aspects of the invention and which comprises the steps of reacting a polyene macrolide antibiotic with a mono or oligosaccharide, the reaction being characterised by the occurrence of a simultaneous Amadori rearrangement, to give the N-glycosyl derivatives of the polyene Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 macrolide antibiotics; isolating the product of the Amadori rearrangement; treating the product with an alkylating agent and purifying the crude product.

In one embodiment of the third aspect of the invention the product of the Amadori rearrangement is isolated in the form of a suspension by precipitation from the solution in which the rearrangement occurs. Organic solvents such as N,N-dimethylformamide are preferred to support the Amadori rearrangement. Organic solvents such as diethyl ether are suitable to effect formation of a suspension by precipitation of the product of the Amadori rearrangement.

In a second embodiment of the third aspect of the invention alkylation of the product of the Amadori rearrangement is carried out at reduced temperature. Temperatures of between -5"C and +5'C are preferred. Alkylating agents such as diazo alkanes may be used. An ethereal solution of diazomethane is the preferred alkylating agent.

Crude N-alkyl-N-glycosyl products can be isolated upon removal of the solvent and precipitation from diethyl ether. The pure product may be isolated using known purification procedures.

Sg A preferred embodiment of the third aspect of the invention comprises a process for preparation of the N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of Spolyene macrolide group presented by general formula wherein M represents residue S: of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue 20 formed by reaction of the antibiotic with mono or oligosaccharidc, preferably with Dglucose, or L-glucose, or D-mannose, or D-galactosc, or lactose, or maltose, and by simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement Nglycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the 25 derivatives in organic solvent, preferably in N,N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the range from -5 C to stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by an excess of diethyl ether, then, the crude product is purified according to known procedures.

A fourth aspect of the invention provides a method of preparation of salts of N-alkyl- N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics of general formula -6- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 2(a) wherein M, R, R 1 and R 2 are as defined above for the first, second and third aspects of the invention and which comprises the steps of suspending an N-alkyl-N-glycosyl derivative prepared according to the third aspect of the invention in sufficient water to effect formation of a homogeneous suspension, acidifying the resulting suspension and isolating the product. The preparation of salts of N-methyl-N-glycosyl derivatives of methyl esters of polyene macrolide antibiotics is especially preferred.

Organic or inorganic acids may be used to acidify the suspension. L-aspartic acid is preferred.

Isolation of the pure product may be effected by precipitation of the crude product with an organic solvent which is then washed with an additional appropriate solvent and dried. It is preferred that the solvent used to precipitate the crude product is miscible with water; acetone is preferred. Typical solvents employed for washing the product include acetone and diethyl ether. It is preferred that the product is dried under reduced pressure.

A preferred embodiment of the fourth aspect of the invention comprises a process for 15 preparation of salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of e polyene macrolide group presented by general formula wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D- S: glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by 20 simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement Nglycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the derivative in organic solvent, preferably in N,N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the *o* 25 range from -50C to +5 0 C, stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by an excess of diethyl ether, then the crude product is purified according to known procedures, subsequently, the obtained derivative.

as a solid, is suspended in small amount of water, and stoichiometric amount of organic or inorganic acid is added, next the product is precipitated from the formed solution by an excess of organic solvent miscible with water, preferably acetone, the solid is then washed.

preferably with acetone and subsequently preferably with diethyl ether, and dried, -7- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCTIGB96/01144 preferably under reduced pressure.

A fifth aspect of the present invention comprises N-alkyl-N-glycosyl derivatives of formula I or salts thereof for use in therapy.

A sixth aspect of the invention provides -a method for the treatment of fungal infections in humans and animals which comprises the administration thereto of N-alkyl-Nglycosyl derivatives of formula 1(a) or salts thereof as herein before defined. N-methyl-Nglycosyl derivatives of formula 1(b) or the salts thereof are of particular interest.

A first preferred embodiment of the sixth aspect of the invention comprises a method for treatment of external and internal fungal infections in humans and animals, wherein Nmethyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula wherein M represents residue of an antibiotic ofpolyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or Dmannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori 15 rearrangement are used to treat the infections.

A second preferred embodiment of the sixth aspect of the invention comprises a method for treatment of external and internal fungal infections in humans and animals, wherein salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene S" macrolide group presented by general formula wherein M represents residue of an 20 antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid are used to treat the infections.

25 A seventh aspect of the invention provides N-alkyl-N-glycosvl derivatives of formula l(a) or salts thereof as herein before defined for use in the treatment of fungal infections.

N-methyl-N-glycosyl derivatives of formula 1(b) or the salts. thereof are of particular interest.

The infections for which treatment is provided may be internal or external. The mode of administration will depend upon the nature of the infection. Thus the compounds of the invention may be formulated for intravenous, intra peritoneal, oral, topical, subcutaneous, -8- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCTIGB96/01144 rectal or vaginal administration.

A eighth aspect of the invention provides compositions for use in the treatment of fungal infections comprising an N-alkyl-N-glycosyl derivatives of formula 1(a) or a salt thereof and a physiologically acceptable carrier. The nature of the N-alkyl-N-glycosyl derivative and the carrier will depend upon the mode of administration. The composition may be formulated from one or more compounds according to the invention, optionally in combination with other known antifungal agents, according to requirements. Compositions containing N-methyl-N-glycosyl derivatives of formula 1(b) or the salts thereof are of particular interest.

An ninth aspect of the invention provides a unit dosage form comprising one or more N-alkyl-N-glycosyl derivative of formula I(a) or salts thereof and a physiologically acceptable carrier formulated for pharmaceutical or veterinary use. The unit dosage form may be formulated from one or more compounds according to the invention optionally in combination with other known antifungal agents. By analogy with the previous aspects of 15 the invention unit dosage forms containing N-methyl-N-glycosyl derivatives of formula l(b) are of particular interest.

As mentioned above the nature of the unit dosage form will depend upon the mode of administration. Typically tablets and capsules are suitable for oral administration; creams and patches are suitable for topical administration with pessaries being suitable for rectal and vacinal administration.

A tenth aspect of the invention provides the use of N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof for the preparation of a medicament for use in the treatment of fungal infections. Compounds wherein the N-alkyl and alkyl ester substituents are both methyl groups are of particular interest.

25 Structural determinations carried out on the compounds of the invention using spectroscopic methods indicate that the integrity of the parent antibiotic is preserved during the reaction.

The invented process for preparation of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group gives the desired products without changes in structure of the parent antibiotic. St-ucture of the obtained compounds was proved using spectroscopic methods. The proof is illustrated by determination of the structure of -9- Mimosa 10/14/1997 13:57:49 WO 96135701 PCTIGB96/0 1144 N-methyl-N-D-fructosylamphotericin B methyl estcr, of formula 3.

OH

O1 OH

OH

HOC HO HO 0 OH OH OH OH 0 COH OH H3C 1 5OH

OH

OH

Formula3 Electronic spectrum of N-methyl-N-D-fructosylamphotcricin B methyl ester is identical with that of the parent antibiotic, that means amphotericin B, and demonstrates that the invented method does not lead to degradation of the polyene chromophore, and a high value of extinction (E 1 I 1cm 1300 at 382 nra) confirms a high purity of the obtained product. Absorption infrared spectrum of the N-methvl-N-D-fructosvlamphote-icin

B

.*methyl ester demonstrates the band related to stretching vibrations of the este.r carbonyl group at 1730 cm' and lack of band of free carboxylic group, what means that the :10 carboxylic group was completely tranisformed into methyl ester group. Complete information on structure of the N-methyl-N-D-fructosylarnphotericin B methyl ester was provided by nuclear magnetic resonance spectra (NNvf) upon IH (DQF-COSY, ROESY), 13 C (DEPT) and heterocorrelated spectra (Varian 300 IMHZ spectrometer) allowed an assig'nment of the formula 3 for the compound.

The most significant IH and 1 3C information are listed in Tables 1 and 2, respectively. The NMNR data for aglycone of amphotericin B are in fuill agreement with literature data Magn. Reson. Chem. 3-1275, (1992)2 P. Sowiiiski. 1. Pawlak. E. Borowski, P. Gariboldi. IH chemical shifts (in DMNSO/iIceOD solvent system) of N-CH 3 (6 2.35 ppm) and H-l' (2.30 and 3.15 ppm) are characteristic for influence of an amino substituent. After acidification 8 chances to 2.92 ppmn for N-CH 3 and to 3.64 for H- I due Mimosa 10/14/1997 13:57:49 WO 96135701 PCTIGB96/0 1144 to the protonation of the amino group (6 for H-3'changes to 3.19 ppm). These data are supported also by ROE effects between protons NCH 3 IH3', NCH 3 /H2' NCH 3 /Hl"b and I Coupling constants and ROE indicate 4 C I conformation of the mycosarnine moiety, as it w-as found before for free amphotericin B.

Table I presents chemical shifts I H and ROE effects of the disaccharide fragment of the N-methyl-N-D-fructosylamphotericin B methyl ester.

Table 1 proton 6[ppm] ROE for protons 6[ppm] ROE for protons pyridine-ds. methanol-d, 9 I DNSO-d methanol-d 4 4 :6 1' 4.77 18b, COOMe 4.48 2' 4.41 V, NNW, 17, COO.Ne, Pa? 4. 04 NNe, COO~ve 3' 2.06 Nrve, Pa, COOMe 1.S9 N~ve, I "b 4' 4.38 6' 3.80 6' 3.61 6' 3.45 6' 6' 1.23 5' 1.27 I a 2.56 3- 2.30 l"b 3.58 W~e 3.15 3' 4.41 1 3.65 1 "b 4.76 3 .97 4.41 3.6 6"a 4.21 3.57 6"b 4.36 3.76 W Ne 2.29 3T, 1l"b, COOMe 2.35 1"a. 1"b, COONe .COONfe 3.70 1P, N~ve, 16 3.77 2',NWe Mimosa 10/14/1997 13:57:49 *S a a WO 9613S701 POY/GB96O I14.4 Table 2 presents 1 3C-NMR chemical shifts of the disaccharide fragment of the N-methyl-N- D-fructosylamphotericin B methyl ester and their comparison with data for D-fructose.

Table 2 data for fructoses' J-D-fructopyranose a-D-furanose P-D-fructofuranose carbon 6 (ppm] 6 [ppm] 6 [pm] 6 [ppm] if 98.2 2' 72.4 3' 66.4 4' 69.8 72.3 6' 18.2 1" 62.2 6.4.1 62.1 63.9 2"98.1 99.1 105.3 102.4 66.9 70.5 83.0 76.5 4" 71.2 68.4 77.0 75.5 72.2 70.0 82.2 81.5 6" 64.6 64.7 62.1 63.3 NI'ei 40.9 COONIe 51.6 S. N. Rosentha J.H. Fendler, Progr. Phvs. Orm. Chem. .11 280 (1976).

-12- Mimosa 10/14/1997 13:57:49 q.

C.

C C

C

C

WO 96135701 PCTIGB96O 1144 Comparison of the 13 C-NMR data from Table 2 for the. fructosyl fragment with literature data for D-fructose indicates the pyranosidc form of the sugar substituent. The observed coupling constants, presented in Table 3, evidence a boat conformation of the fructopyranoside ring presented by formula 4. Only this conformation of the ring is in full agreement with the measured coupling constants.

Table 3 presents coupling constants JHfor protons of the disaccharide fragment of the N-methyl-N-D-fructosylarnphotericin B methyl ester (pyridine-d 5 methano-d 4 9 coupling constants and chemical shifts of closely coupled spin system HY" H6" were refined iteratively by computer simulation.

Table 3 protons J (Hz] protons__J 2' o",4 4' ~9.54,5"80 9.2 5"1, 61'a 5.76 6.0 6"b 3.61 6"a, 6"b -10.86 ,6"a -0.1 10 The presented results confirm the conformation of the fructosyl fragmcnt of the N-mcthyl.

N-D-fructosvlamphoter-icin B methyl ester presented by formula 4. Other N-methyl-Nclycosyl derivatives of methyl esters of antibiotics of polvlene macrolide group were characterized by methods simidlar to those described above.

O H N 3

OH

Formula 4 -13- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCI/GB96/01144 The invention will now be described by reference to the following non-limiting examples. Further embodiments falling within the scope of the invention will be apparent to a skilled person.

Anti-fungal Activity For all of the prepared compounds antifungal activity and also toxicity in vitro were determined. For the compound with the best properties, that means for the N-methyl-N-Dfructosylamphotericin B methyl ester aspartate, activity and toxicity in vivo were also determined.

In Vitro Antifungal Activity The antifungal activity of compounds was determined following the standard for polyene macrolides procedure. The liquid Sabouraud medium was inoculated with 104 cells/ml of test organism Candida albicans ATCC 262778 and incubated for 24 hours at 30"C with the tested antibiotic (serial dilutions). Amphotericin B was used as the reference. Compounds were dissolved in DMF and suitable amounts of the solutions were Sadded to the medium. Turbidimetric method (660 nm) was applied to determine the degree of growth inhibition. The concentration of antibiotic at which the growth of fungi was inhibited by 50% was determined from the dose response curve. The obtained IC 5 0 value characterized antifungal activity of the compound.

10 In Vitro Toxicity Toxicity of compounds in vitro against animal cells was determined using standard for polyene macrolides procedure, by the determination of the degree of haemolysis of human erythrocytes. Human erythrocytes isolated from fresh, citrated human blood were washed twice with cold saline. The cells were diluted 250 times with saline and 15 equilibrated for 30 minutes at 37 0 C. Samples of erythrocytes were incubated with various concentrations of antibiotics (the base solution in DMF) for 30 minutes at 37"C. After centrifugation the lysis of erythrocytes was assessed by determination of the haemoglobin released to the solution. Optical density of the supernatant was measured at 550 nm. The results were expressed by EH 50 value, as concentration of antibiotic at which 50% of hemolysis occurred. The values of EH 5 0 were read from a curve relating the degree of hemolysis with antibiotic dose.

In Vivo Toxicity -14- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 In vivo toxicity was determined for methyl ester of N-methyl-N-Dfructosylamphotericin B L-aspartate as the maximum tolerated dose (MTD), and as the acute toxicity (LD 5 0 To determine MTD dose the compound was dissolved in solution of glucose, and administered intravenously and intraperitonealy to Balb/c mice in single and multiple doses. The maximum single tolerated dose was 100 mg/kg for the intravenous and more than 200 mg/kg for the intraperitoneal administration. The maximum multiple tolerated dose for intraperitoneal administration of 100 mg/kg for 5 days was much higher. For such dose, toxic effects were not observed during 20 days of observation.

The acute toxicity, LD 5 0 of methyl ester of N-methyl-N-D-fructosylamphotericin

B

L-aspartate was determined for Swiss Webster female mice of average weight of 20 g.

Various doses of the tested compound, and for comparison, amphotericin B in form of Fungizone, dissolved in 5% glucose were given intravenously to the animals. The administered volume of the solution was 0.5 ml. 0.5 ml of 5 solution of glucose was administered to mice as a control. Every dose of both preparations was administered to 15 5 mice. The animals were observed for 7 days. Next, the animals were killed, and some serum indexes were determined. No increased level of aspartate aminotransferase or creatinine were found in comparison with the control. For methyl ester of N-methyl-N-Dfructosylamphotericin B L-aspartate, the LD 5 0 was found to be 400 mg/kg, while for amphotericin B in form of Fungizone it was 6 mg/kg.

20 Chemotherapeutic Efficacy Chemotherapeutic efficacy of methyl ester of N-methyl-N-D-fructosylamphotericin B L-aspartate was determined using systemic murine candidose model. Candida albicans was grown overnight in Sabouraud dextrose broth at room temperature. The fungal cells were centrifuged, washed twice with 0.9 solution of sodium chloride, and suspended in 25 physiological salt solution. Female Swiss Webster mice of 25 g weight, were injected intravenously with 105 cells of Candida in 0.2 ml of 0.9 sodium chloride solution.

Initially, the infection was systemic, but by 2 to 3 days it was localized to the kidneys.

Untreated animals usually died between 7 to 14 days post-infection. Three days post-infection, animals were treated intravenously, twice a day, for 5 consecutive days with a 5 to 6 hours interval. Preparation was administered as a solution in 5% glucose. The animals were observed for 5 weeks starting from the day of infection. After this time. the Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 surviving animals were sacrificed their kidneys were removed, homogenized in sterile water, and the homogenate was plated on Sabouraud dextrose agar, and the grown colonies of Candida were counted. The chemotherapeutic effectiveness was represented as a dose of mg/kg, which in the above test resulted in a survival of 50 of animals, and on clearance of Candida from kidneys of half of the mice. The dose, called ED 5 0 was calculated using a method given in J. Hyg. 27,493, (1938). The values of ED 5 0 for methyl ester of N-methyl-N-D-fructosylamphotericin B L-aspartate are 2.3 mg/kg based on the survival, and 6 mg/kg based on the kidneys clearance.

Preparative Examples N-Methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group, their salts, and methods of preparation are illustrated by the examples given below.

Example I.

1 g ofamphotericin B (El%lcm 1350 at 382 nm, MeOH) was dissolved in 15 ml of N,N-dimethylformamide, 0.3 g of D-glucose was added, and the mixture was stirred in 5 a •15 darkness at 37"C for 40 hours. Next the reaction was cooled and a solid was precipitated 0 with an excess of diethyl ether. The solid was centrifuged, washed twice with diethyl ether and dried under reduced pressure. To remove an excess of glucose the solid was suspended in 20 ml of water, centrifuged, washed twice with small amount of water, twice with acetone, and next twice with diethyl ether. The product was dried under reduced pressure 20 to give 0.98 g ofN-D-fructosylamphotericin B (El%lcm 1200 at 382 nm, MeOH). The product was dissolved, with stirring, in 10 ml of N,N-dimethylformamide and 50 ml of diethyl ether was added to the solution, to give a fine suspension. The suspension was cooled in ice to 0 2*C, and freshly prepared diethyl ether solution of 2.5 mole of S* diazomethane per 1 mole of N-D-fructosylamphotericin B, was added with vigorous 25 stirring. The reaction was followed by thin layer chromatography on silica gel in chloroform methanol water 10:6:1 v/v solvent system. After completion of the reaction.

what took about 2 hours, the excess of diazomethane and diethyl ether was evaporated under reduced pressure at temperature not higher than 40*C. The crude product was precipitated from the residue with an excess ofdiethyl ether, centrifuged, washed twice with diethyl ether, next with n-hexane, and dried under reduced pressure to give 0.95 g of the -16- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 crude product. Pure N-methyl-N-D-fructosylamphotericin B methyl ester was isolated from the crude product by column chromatography on Merck Silicagel 60, 70 -230 mesh in chloroform methanol water20 8 1 v/v solvent system. Thus, 0.95 g of the crude product was suspended in the mixture of solvents specified above, and if the product dissolved with difficulties, proportions of the same solvents were changed to 10 6 The undissolved part was centrifuged off, and the supernatant charged on chromatography column, next developed in the solvent mixture listed above, but in proportion 20 8 1 v/v.

The eluate was analysed on silica plates using chloroform methanol water 10 6 1 v/v solvent system. The plates were visualized with cerium sulphate reagent. Fractions of Rf 0.5 0.54 containing pure N-methyl-N-D-fructosyl derivative of amphotericin B methyl ester were collected. The combined fractions were evaporated under reduced pressure. The dry residue was dissolved in small amount of N,N-dimethylformamide, and the product was precipitated with an excess of diethyl ether, the solid was centrifuged, washed twice with diethyl ether and dried in a vacuum desiccator. 0.137 g of N-methyl-N- 15 D-fructosylamphotericin B methyl ester, Ellcm 1300 on 382 nm in methanol, was obtained. The proof of structure was given above in the descriptive part. Antifungal activity of the compound against Candida albicans, determined as it was described above, gave IC 5 0 0.12 pg/ml, and toxicity for human erythrocytes, determined as described above, gave EH 5 0 value higher than 350 pg/ml. For comparison, EH50 value for the 20 starting amphotericin B was 1.5 pg/ml. An exact value of EH 5 0 for N-methyl-N-Dfructosylamphotericin B methyl ester could not be determined, as above 350 pg/ml the compound was insoluble under conditions of the experiment.

9 Example II.

0.5 g of candidin (El%cm 1175 at 382 nm, MeOH) and 0.15 g of D-glucose were 25 dissolved in 10 ml of N,N-dimethylfonramide and stirred at 37 0 C for 36 hours. Further procedure was analogous to this of the Example I, and resulted in 0.43 g of N-D-fructosylcandidin, El%lci 1100 at 382 nm in MeOH. The product was methylated with diazomethane in diethyl ether, analogously as in the Example I to give 0.4 g of crude product. Pure N-methyl-N-D-fructosylcandidin methyl ester was isolated by column chromatography, by method similar to that given in the Example I. Fractions containing -17- Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 pure derivative were characterized on thin layer chromatography by Rf 0.49 0.52. The fractions were combined, evaporated to dryness, dissolved in small amount of N,N-dimethylformamide, and solid was precipitated with diethyl ether. The solid was centrifuged, washed with diethyl ether and dried in vacuum desiccator to give 0.05 g of N-methyl-N-D-fructosylcandidin methyl ester; El%lcm 1200 at 382 nm, in MeOH,

IC

5 0 0.75 pg/ml and EH 5 O above 300 pg/ml. Structure of the compound was determined by the same methods as for of N-methyl-N-D-fructosylamphotericin B methyl ester.

Example III.

2 g of nystatin (El%icm 870 at 304 nm, in MeOH) and 0.6 g of D-glucose were dissolved in 35 ml of N,N-dimethylacetamide and stirred at 37"C for 40 hours. After completion of the reaction the crude product was precipitated with diethyl ether, centrifuged, and dried under vacuum. Then, an excess of glucose was washed off with small amount of water acetone 1 I mixture, next with acetone, diethyl ether, and the product was centrifuged and dried in vacuum desiccator to give 1.2 g of 15 N-D-fructosylnystatin (E cm= 720 at 304 nm, in MeOH). The product was methylated using diazomethane as in the Example I to give 1.25 g of crude product. The product was purified on silica gel column as in the Example I. Fractions containing pure N-mcthyl-N-Dfructosylnystatin methyl ester were characterized on thin layer chromatography by Rf 0.49 0.52 as in the Example 1. The fractions were combined, evaporated to dryness at 30*C under reduced pressure, dissolved in small amount of N,N-dimethylformamide, and ~product was precipitated with diethyl ether. The product was centrifuged, washed with diethyl ether and dried in vacuum desiccator to give 0.17 g of N-methyl-N-Dfructosylnystatin methyl ester; El%lcm 900 at 304 nm, in MeOH. Structure of the "compound was determined by a method described for N-methyl-N-D-fructosylamphotericin 25 B methyl ester. For the obtained compound IC 5 0 6.8 pg/ml and EHO0 above 300 pg/ml were found.

Example IV.

0.79 g of vacidin. the main component of antibiotic complex aureofacin, (El%lcm 900 at 378 nm, in MeOH) and 0.22 g of D-glucose in 15 ml of N.N-dimethylacetamide were

-IS-

Mimosa 10/14/1997 13:57:49 WO 96/35701 PCT/GB96/01144 stirred at 37*C for 18 hours. After completion of the reaction the mixture was cooled and solid was precipitated with an excess ofdicthyl ether. The solid was centrifuged, washed with diethyl ether and dried under reduced pressure to give 0.8 g of crude N-Dfructosylvacidin (El%icm 720 at 378 rn, in MeOH). The obtained derivative was methylated using diazomethane, as in the Example I to give 0.5 g of crude product. Pure N-methyl-N-D-fructosylvacidin methyl ester was isolated by chromatography on silica gel column similarly as it was described in the Example 1, but the column was developed with chloroform methanol water 30 8 1 solvent system. Fractions containing pure derivative ofvacidin and having on thin layer chromatography value of Rf= 0.53 0.55 in chloroform methanol water 13 8 1 solvent system were collected and combined.

Further procedure was as in the Example III. 0.07 g of N-methyl-N-D-fructosylvacidin methyl ester was obtained (El% 1 cm 900 at 378 nm, in MeOH). The compound exhibited

IC

5 0 0.01 .g/ml and EH 5 0= 170 gg/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

15 Example V.

"0.79 g of candicidin D, the main component of antibiotic complex candicidin, was treated identically as described in the Example IV. 0.1 g ofN-methyl-N-D-fructosylcandicidin D methyl ester was obtained; Ellcm 920 at 378 unm, in MeOH, Rfof the compound in 4*@ thin layer chromatography, under conditions described in the Example IV, was 0.50 0.53.

20 The compound exhibited IC 5 0 0.01 lg/mI and EH50 180 ug/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

Example VI.

0.79 g of the main component of antibiotic complex trychomycin was treated identically as it was described in the Example IV. 0.1 g of N-methyl-N-fructosyltrychomycin methyl ester was obtained; El%lcm 910 at 378 nm. in MeOH Rfof the compound in thin layer chromatography, under conditions described in the Example IV, was 0.49 0.52. The compound exhibited IC 5 0 0.013 pg/ml and EH 5 0 165 ig/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin -19- Mimosa 10/14/1997 13:57:49 WO 96135701 PCrIGB9611144 B methyl ester.

Example VII.

g of amphotericin B (E 1 0 1cm 1350 at 3 82 urn, MeOH) and 0. 15 g of L-glucosc in 8 ml of N,N-dimethvlformnamide was stirred at 37-C for 40 hours. Subsequent operations were as in the Example 1. 0.065 g of N-methyl-N-L-fructosylamphotericin

B

methyl ester was obtained; El O/icm 1280 at 382 n, in MeOH-. The compound exhibited IC 5 0 0.42 p~g/ml and EH 5 0 above 200 ;igfmI. Structure of the compound was determined by a method described for methyl ester of N-methyl-N-Dfructosylamphotericin B.

Example VIII.

0.52 g of amphotericin B (El'/icm =1350 at 382 rim, M~eOH) and 0.153 g of D-mannose e~g. was dissolved in 10 ml of N,N-dirnethylforrnamide and stirred at 37*C for 40 hours.

Subsequent operations were as in the Example 1. Pure derivative was isolated by silica gel see:**column chromatography, iii a manncr analogous to that of the Example I, fractions having in thin layer chromatography, run according to the method described in the Example I.

:0::value of Rf =0.53 0.55 were. collected. Subsequent operations were as in the Example 1.

0.08 g of N-methyl-iN-D-fructosylamphot-ericin B methyl ester was obtained; *E'~icm 1280 at 382 un, in MveOH. The compound exhibited IC 5 0 0.42 [pg/mI and

EH

5 0 above 200 pgI. Structure of the compound was determined by a method describe-d 020 for N-mcthyl.N-D-fructosylamphot-ericin B me-thyl ester.

a 0 :00 Example IX.

0.5 g of amphotericin B (El%jljm 1350 at 382 amn, IMeOH) and 0.3 g of D-lactose in 12 ml of N,N-dimethylformamide- was stirred at 37*C for two days. Subsequent operations were as in the Example 1. Pure derivative was isolated by silica gel column chromatography, in a manner analogous to that of the Example 1, fractions havina in thin layer chromatogrTaphy. run according to the method described in the Example I. value of Rf =0.25 0.30 were collected. 0.08 9- of N-methyl-N-D-fructosyl-galactosvlamphotericin B methyl ester was obtained: E1% 1cm =1000 at 382 run, in MeOH. The compound Mimosa 10/14/1997 13:57:49 WO 96/35701 PCTIGB96/01144 exhibited IC 5 0 6.0 pg/ml and EH50 above 200 ug/ml.

Example X.

g of N-methyl-N-D-fructosylamphotericin B methyl ester, prepared according to the Example 1, was suspended in 10 ml of water and 0.059 g of aspanic acid dissolved in 2 ml of water was added. The solution of acid was added dropwise, with stirring to effect the solution. The solution was filtered to remove a small amount of residual solid and an excess of acetone was added to the clear filtrate until the whole salt was precipitated. The solid was filtered off or centrifuged, washed twice with acetone, twice with diethyl ether and dried under reduced pressure, 0.5 g of methyl ester of N-methyl-N-Dfructosylamphotericin B L-aspartate, El%icm 1100 at 382 nm, in MeOH, was obtained.

Thin layer chromatography under conditions as in the Example I gave Rf 0.5 0.54.

Product was soluble in N,N-dimethylformamide, dimethylsu!phoxide and 5% water solution ,of glucose. It was very well soluble in water. The compound exhibited IC 5 0 0.125 g/ml and EH 5 0 above 350 pg/ml.

o a -21- -21- Mimosa 10/14/1997 13:57:49

Claims (26)

1. An N-alkyl-N-glycosyl derivative of a poiyenc macrolidc antibiotic Of gOeneral formula I1(a), M-COOR 2 R 1 -N-CH2 I/ HO R) I (a) wherein M4 represents a residue of a polyene inacrolide antibiotic, R represents a part of sug-ar residue formed by reaction of the antibiotic with a mono or oligosaccharide, R I represents a C 1- 4 alkyl group and R 2 represents a CI1A- alkyl group.

2. An N-alkyl-N-glycosyl derivative of a polyene macrolide antibiotic according to .:Claim 1 wherein Mf is selected fromn the group consisting of arnphotet-icin B, candidin, candidoin, candidiain, mycoheptin, nystatin, polyfunigin, aureofacin, ;:vacidin, trichornycin and adcin

3. An N-alkyl-N-glycosyl derivative of a polyene macrolide antibiotic according to Claim I or Claim 2, wherein R is part of a sugar residue formed by reaction of the antibiotic with a mono- or oligosaccharide with simultaneous amadori rearrangement.

4. An N-alkyl-N-glycosy[ derivative of a polyene macrolide antibiotic according any one of claims I to 3 wherein the mono or olig-osaccharide from which the sug-Ar residue R is derived is sclected from the group oonsisting of D-glucosc, L- glucose, D-rnannose. D-galactose, lactose and maltose. An N-meThyl.N-glycosyl derivative of a polyene macrolide antibiotic of formula I1(b) M-COOCH 3 HjC -N-CH 2 O) HO R I (b) wherein MI represents a residue of a polvene mnacTolide antibiotic and R represents a Fart of sugar residue forrncd by reaction of the antibiodc wi th a mono or oligosaccharide.

6. An N-alkyl-N-glycosyl derivative of a polyene rnacrolide antibiotic according to any one of claims I to 4, wherein R 2 is a methyl group).

7. A salt of an N-alkyl-N-glycosyl derivative of a polyenc rnacrolide antibiotic of formula 2(a) M-COOR 2 e R 1 -N-CH 2 A HO R 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, RI represents a CI- 4 alkyl group, R2represents a C 1 4 alkyl group and A represents an anion of an organic or inorganic acid.

8. A salt according to Claim 7, wherein NI is selected from the group consisting of amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, .:goo:polyfungin, aureofacin, vacidin, trichomycin and candicidin.

9. A salt according to Claim 7 or Claim 8, wherein R is part of a sugar residue formed by rcEtction of the antibiotic with a mono- or oligosaccharidc with simultaneous arnadori rearrangement. A salt according to any one of claims 7 to 9, wherein the mono- or oligosaccharide from which the sugar residue R is derived is selected from the group consisting of D-glucose, L-glucose, D-mannose, D-galactose, lactose and maltose.

11. A salt of an N-rnethyl-N-glycosyl derivative of a polycnc rnacrolide antibiotic of formula 2(b) M-COOCH 3 H3--CH 2 f Ae HO R 2(b) wherein NI represents a residue of a polyene rnacrolide antibiotic, R represents a part Of sug-ar residue formed by reaction of the antibiotic with a mono or oligosaccha-ide and A represents an anion of an organic or inorganic acid.

12. A salt according to any one of claims 7 to 10, wherein R2 is a methyl group.

13. A salt of according to any one of claims 7 to 12, wherein A is the anion of L- aspar-tic acid.

14. A method of preparation of an N-alkyl-N-glycosyl derivative of an antibiotic of a polvene inacrolid-, of formula I1(a) 4 M-COOR 2 R 1 -N-CH 2 S..0) wherin Mrepresents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligos0accharide, R I represents a C 1- alkyl group and R. 2 represents a C 1 4 aLicyl group, which includes the steps of reacting a polyene macrolide antibiotic with a mono or oligosaccharide with simultaneous amadori rearrangement, to give the N-clycosyl derivative of the polyene macrolide antibiotic; isolating the amadori rearrangement product; and treating the isolatcd amadori rearrangement product with an alkylating agcnt. A method of preparation according to claim 14, wherein arnadori rearrangement product is isolated in the form of a suspension by precipitation from the solution in which the rearrangernent occurs.

16. A method of preparation according to Claim 14 or Claim 15, wherein N,N- dimethylformamidc is used to support the amadori rearrangement.

17. A method of preparation according to any one of claims 14 to 16, wherein diethyl ether is used to effect formation of a suspension by precipitation of the product of the amadori rearrangement.

18. A method of preparation according to any one of claims 14 to 17, wherein alkylation of the product of the amadori rearrangement is carried out at reduced temperature.

19. A method of preparation according to Claim 18, wherein alkylation is carried out at temperatures of between -5*C and A method of preparation according to any one of claims 14 to 19, wherein the alkylating agent is an ethereal solution of diazomethane.

21. A method of preparation of a salt of an N-alkyl-N-glycosyl derivative of a polyene macrolide antibiotic of general formula 2(a) M-COOR 2 I R -N-CH 2 A :H HO R 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, R 1 represents a C1-4 alkyl group, R 2 represents a C1-4 alkyl group, and A represents an anion of an organic or inorganic acid, which includes the steps of suspending an N-alkyl-N-glycosyl derivative of formula as defined in any one of claims I to 6, in sufficient water to effect formation of a homogeneous suspension, acidifying the resulting suspension and isolating the product.

22. A method of preparation of a salt of an N-alkyl-N-glycosyl derivative of a polyene macrolide antibiotic according to Claim 21 wherein an organic or inorganic acid is used to acidify the suspension.

23. A method of preparation of a salt of an N-alkyl-N-glycosyl derivative of a polyene macrolide antibiotic according to Claim 22 wherein L-asparric acid is used to acidify the suspension.

24. A method for the treatment of a fungal infection in a human or non-human patient, which includes the administration thereto of an N-alkyl-N-glycosyl derivative of formula l(a) or a salt thereof of formula 2(a), -e M-COOR 2 M-COOR 2 S I 1 R'-N-CH2 RI-N-CH2 AG A A\ H AC HO R HO R I(a) 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, R 1 represents a C 1 4 alkyl group, R2 represents a Ci-4 alkyl group, and A represents an anion of an organic or inorganic acid.

25. A method according to Claim 24, in which the N-alkyl N-glycosyl derivative of formula 1(a) or 2(a) is administered by perfusion.

26. A composition including an N-alkyl-N-glycosyl derivative of formula 1(a) or a salt thereof of formula 2(a), M-COOR 2 M-COOR 2 R 1 -N-CH 2 R 1 -N-CH2 A /0 I A C H C HO R HO R S(a) 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, Ri represents a C 1 -4 alkyl group, R 2 represents a CI alkyl group, and A represents an anion of an organic or inorganic acid and a physiologically acceptable carrier.

27. A composition according to Claim 26, wherein the composition is in the form of 26 a unit dosage formr.

28. A composition including an N-rnethyl-N-glycosyl derivative of formula I1(b) or a salt thereof of formula 2(b) E) M-COOCH 3 M COOCH 3 H 3 C-N-CH 2 H 3 C-N-CH 2 e 0 /0 A HO I/ R HO R I(b) 2(b) wherei M represents a residue of a polyenc macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide and.A represents an anion of an organic or inorganic acd and a physiologically acceptable carrier. :29. A composition according to any one of claims 26 to 28, which further includes a known anti-fungal agent. A composition according toayoeof claims 26 to 29 which is formulated for intravenous, intra peritoneal, oral, topical, subcutaneous, rectal or vaginal administration. 0% 31. Use of an N-alkyl-N-glycosyl derivative of formula 1(a) or a salt thereof of formula 2(a), 2 2 M-COOR 2 M-COOR 2 R' -N-CH2 R-N-C H 2 H: 0) HO *R HO R I(a) 2(a) wherein MLv represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, RI represents a C 1 alkyl group, R2represents aC1 alkyl Vroup, and A represents an anion of an organic or inorganic acid in the preparaticnn of a mnedicament for use in therapy.

32. Use of an N-alkyl-N-glycosyl of formula 2(a), M-COOR 2 R N--CH 2 0 OH R/ 1(a) derivative of formula 1(a) or a salt thereof M-COOR 2 R 1 -N-CH 2 0 R OH RZ 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, R' represents a C,.1 alkyl group, R 2 represents a C,.4r alkyl group, and A represents an anion of an organic or inorganic acid in the preparation of a medicament for use in the treatment of a fungal infection in a human or animal patient. 4 a a a a a 9

33. An N-alkyl-N-glycosyl derivative of formula 1(a) or a salt formula 2(a), thereof of A M-COOR 2 R'-N-CH 2 0 OH R 1(a) M-COOR 2 C cOH R oH/\ R) 2(a) wherein M represents a residue of a polyene macrolide antibiotic, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, R 1 represents C1-4 alkyl group, R 2 represents a C1-4 alkyl group, and A represents an anion of an organic or inorganic acid for use in the treatment of a fungal infection in a human or animal patient. DATED this 13th day of January, 2000 BRITISH TECHNOLOGY GROUP LIMITED WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P10225AU00 LCG/CLR/SXH e